[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intestinal-metaplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intestinal-metaplasia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,90,110,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634666","association-between-microplastic-exposure-and-the-pathological-progression-of-gastric-carcinogenesis-100634666",false,"NCT07542652","Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis","Association of Microplastic Exposure With Pathological Stages of Gastric Mucosal Carcinogenesis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Aged between 18 and 75 years old, gender is not restricted\n* Having a clear diagnosis result within the recent three months and being diagnosed with chronic non - atrophic gastritis, precancerous lesions of gastric cancer, or gastric cancer for the first time\n* Have clear Helicobacter pylori (Hp) test results\n* Be in normal mental state and able to independently complete the questionnaire survey\n\nExclusion Criteria:\n\n* Patients with a history of malignant tumors in other parts\n* Patients who have previously undergone upper gastrointestinal surgery, chemotherapy, or radiotherapy\n* Patients with severe diseases of major organs such as the heart, lungs liver, and kidneys\n* Patients who are currently receiving psychological intervention or taking psychiatric drugs\n* Pregnant or lactating women\n* Patients with severe missing clinical data or questionnaire information\n* Refusing to sign the informed consent form","ALL","18 Years","75 Years",{"count":20,"type":21},450,"ESTIMATED","OBSERVATIONAL","The objective of this clinical trial is to explore the correlation between the level of microplastic exposure and the risk of gastric mucosal carcinogenesis, and to evaluate the strength of its effect as an independent risk factor. The main questions it aims to answer include: Does the level of microplastic exposure increase the risk of gastric mucosal carcinogenesis? Can the correlation between the level of microplastic exposure and gastric mucosal carcinogenesis, as well as the sources of high - risk microplastic exposure, be explored through a questionnaire on external microplastic exposure? Researchers will complete a design structured questionnaire and ask participants to fill it out carefully and truthfully to determine whether the level of microplastic exposure increases the risk of gastric mucosal carcinogenesis.",[25,26,27,28],"Gastric Carcinoma","Gastritis Chronic","Intestinal Metaplasia","Gastric Precancerous Lesions","RECRUITING","2026-04-25",{"date":32,"type":33},"2026-04-30","ACTUAL",{"date":35,"type":33},"2026-03-31",{"date":37,"type":21},"2026-12-31",{"name":39,"class":40},"Yongquan Shi","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100619584","endoscopic-screening-of-asymptomatic-patients-for-helicobacter-pylori-intestinal-metaplasia-and-barretts-mucosa-during-screening-colonoscopy-100619584","NCT07346521","Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy","Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy - a Cross-sectional Study","G-SCOGE","Inclusion Criteria:\n\n* Age ≥ 30 years\n* Scheduled screening colonoscopy (either initial screening or surveillance following previously detected polyps)\n* Asymptomatic (no gastrointestinal symptoms)\n* Willingness and consent to undergo simultaneous gastroscopy with biopsy sampling\n* Written informed consent to participate in the study, including the use of histological findings and patient data for study analysis\n\nExclusion Criteria:\n\n* Known Helicobacter pylori infection or previous treatment for H. pylori\n* Current or recent proton pump inhibitor (PPI) therapy (\\\u003C 4 weeks)\n* Pre-existing gastrointestinal diseases (e.g., chronic gastritis, ulcer, gastric carcinoma)\n* Immunosuppression or relevant underlying diseases\n* Refusal to undergo additional gastroscopy or biopsy",true,"30 Years",{"count":53,"type":21},1000,"The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy.\n\nEndoscopic screening of the stomach is yet not acceptet as a standard screening procedure in Western countries. However, Helicobacter pylori infection is known to increase the risk of developing gastric cancer.\n\nThis study will look at the prevalence of Helicobacter pylori infection in asymptomatic patients who have an additional gastroscopy during the same session as their screening colonoscopy. It will also record other early tissue changes or risk factors for stomach cancer, such as intestinal metaplasia and Barrett's mucosa.\n\nThe main questions this study aims to answer are:\n\n* How often is Helicobacter pylori found in adults without upper gastrointestinal symptoms by use of OGD?\n* Are there any correlations between H. pylori infection and other risk factors, such as BMI, smoking, alcohol consumption, or a family history of colorectal and\u002For stomach cancer?\n\nAbout 1000 participants are expected to take part. Adults undergoing a screening colonoscopy at a private endoscopy center will be offered the chance to have an additional gastroscopy if they meet the study's inclusion criteria (no previous Helicobacter pylori infection and no upper gastrointestinal symptoms).\n\nSmall tissue samples (biopsies) will be taken from the stomach and lower esophagus during the gastroscopy. Biopsies will be checked histologically for the presence of Helicobacter pylori and early tissue changes.\n\nDuring the gastroscopy, no additional procedures or biopsies will be done beyond what is normally performed during a routine examination. Everything done during this procedure follows the standard steps of a regular gastroscopy.\n\nAll data will be coded to protect participant privacy. Researchers will use statistical methods to find out how common Helicobacter pylori infection is and whether it is related to other lifestyle or family risk factors or tissue changes.",[56,27,57],"HELICOBACTER PYLORI INFECTIONS","Barett's Esophagus","2026-03-05",{"date":60,"type":33},"2026-03-09",{"date":62,"type":33},"2025-12-16",{"date":64,"type":21},"2026-12-16",{"name":66,"class":40},"Sigmund Freud PrivatUniversitat",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":75,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100443403","helicobacter-pylori-atrophic-gastritis-and-intestinal-metaplasia-registry-and-prospective-study-100443403","NCT05053945","Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study","Inclusion Criteria:\n\n* Adults \\>= 18 years of age\n* Written informed consent obtained\n* Diagnosed with current or past H. pylori infection,\n* Histologically proven atrophic gastritis (body and\u002For antrum of stomach), intestinal metaplasia (complete and incomplete), dysplasia (any grade) and\u002For gastric cancer (post- treatment)\n\nExclusion Criteria:\n\n* Co-morbid illness that prohibit endoscopic surveillance\n* Declines for study questionnaire, biobanking of specimens and\u002For regular review per study protocol",{"count":74,"type":21},260,"3 Years","Since much is unknown about factors that lead to progression of the pre-neoplastic lesions and cancer. In addition, there is ongoing debate on the optimal surveillance intervals and techniques. To solve these important clinical questions, the establishment of a registry for a longitudinal study is planned.",[78,79,27],"Helicobacter Pylori","Atrophic Gastritis","2024-08-28",{"date":82,"type":33},"2024-08-29",{"date":84,"type":33},"2020-05-15",{"date":86,"type":21},"2025-12-31",{"name":88,"class":40},"Chinese University of Hong Kong",2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":41},"100426980","prediction-of-gastric-cancer-in-intestinal-metaplasia-and-atrophic-gastritis-100426980","NCT04840056","Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis","Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis - Application of Artificial Intelligence in Histology and Clinical Data","GIMA","Inclusion Criteria:\n\n* Adults \\>= 18 years of age\n* Histologically proven atrophic gastritis or intestinal metaplasia (at antrum and\u002For body and\u002For angular of stomach)\n\nExclusion Criteria:\n\n\\- none",{"count":99,"type":21},1300,"The primary objectives of this study are:\n\n* To identify clinical or histological factors associated with gastric cancer development in patients with IM and AG\n* To establish a machine learning algorithm for prediction of future gastric cancer risks and individual risk stratification in patient with IM and AG",[102,27,79],"Gastric Cancer",[104],"artificial intelligence",{"date":82,"type":33},{"date":107,"type":33},"2021-04-15",{"date":86,"type":21},{"name":88,"class":40},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":41},"100502116","the-prevalence-risk-factors-and-optimal-biopsy-protocol-of-be-100502116","NCT05818072","The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE","The Prevalence, Risk Factors and Optimal Biopsy Protocol of Barrett's Esophagus in Taiwan - A Prospective Randomized Study","Inclusion Criteria:\n\n* Adults with columnar-lined esophagus\n\nExclusion Criteria:\n\n* A prior history of endoscopic treatment for Barrett's Esophagus\n* A prior history of upper gastrointestinal malignancy\n* A prior history of total or subtotal gastrectomy\n* Esophageal varices noted during the procedure\n* Uncontrolled coagulopathy\n* Taking antiplatelet drug or anticoagulant","20 Years",{"count":119,"type":21},165,"INTERVENTIONAL",[122],"NA","Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.",[125,27],"Barrett's Esophagus",[125,127,128],"Columnar-lined esophagus","Intestinal metaplasia","2023-05-09",{"date":131,"type":33},"2023-05-11",{"date":133,"type":33},"2023-03-13",{"date":37,"type":21},{"name":136,"class":40},"E-DA Hospital",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":120,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":41},"100409598","surveillance-of-premalignant-stomach---individualized-endoscopic-follow-up-100409598","NCT04613570","SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up","SUPREME","Inclusion Criteria:\n\n* Patients scheduled for upper GI endoscopy with indication for gastric biopsies, including those with known gastric pathology (e.g. auto-immune gastritis) or premalignant conditions (e.g patients under surveillance because of atrophic gastritis);\n* Age above 45 years old\n\nExclusion Criteria:\n\n* History of previous gastrectomy;\n* History of endoscopic resection of neoplastic lesion\n* History of previous gastric dysplasia (even with no detectable lesion)\n* Hereditary syndromes that increase gastric cancer risk (familial adenomatous polyposis; Lynch syndrome)\n* Serious comorbidities (ASA 3 or more)\n* Medication with anticoagulants","45 Years",{"count":146,"type":21},912,[122],"Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for gastric cancer and, therefore, are considered gastric premalignant conditions. Although current guidelines recommend surveillance of individuals with these conditions, the best method for its identification and staging (histological vs endoscopy) and the best time schedule for follow-up are still controversial. Aims: To describe for the first-time patients with premalignant conditions both clinically (familial history), histologically (OLGA\u002FOLGIM; complete\u002Fincomplete metaplasia) and endoscopically (EGGIM) using validated scales and to describe evolution of these parameters through time. To estimate prospectively the gastric cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up for the several stages considering clinical, histological and endoscopic factors.\n\nMethods: Multicenter study involving different gastroenterology departments from several countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of these centers will be evaluated by High-Resolution- endoscopy with virtual chromoendoscopy and EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and\u002For random biopsies (if no areas suspicious of IM) in antrum and corpus will be made and OLGA\u002FOLGIM stages calculated. Patients will be evaluated in clinical consultation and database will be fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At that occasion, all the patients with EGGIM\\>5 and\u002For OLGA III\u002FIV and\u002For OLGIM III\u002FIV will be randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be scheduled for patients with EGGIM 1-4 and OLGIM I\u002FII at 3 and 6 years (SUPREME II). For individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6 years after will be proposed (SUPREME III).",[79,27,150,102],"Gastric Dysplasia",[152,153,154,155,156],"atrophic gastritis","gastric cancer","intestinal metaplasia","gastric dysplasia","surveillance","2022-03-29",{"date":159,"type":33},"2022-03-31",{"date":161,"type":33},"2021-01-02",{"date":37,"type":21},{"name":164,"class":40},"Instituto Portugues de Oncologia, Francisco Gentil, Porto"]